Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT01421004
- Locations
- 🇺🇸
Rush University Medical Center Rush 3, Chicago, Illinois, United States
🇺🇸City of Hope National Medical Center SC-2, Duarte, California, United States
🇺🇸University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, United States
Fingolimod -Response According to Coping - Evaluation
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT01420055
- Locations
- 🇫🇷
Novartis Investigative Site, Tours Cedex, France
Drug Use Investigation for REVOLADE (ITP)
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5797
- Registration Number
- NCT01416311
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
- Conditions
- Plaque-type Psoriasis
- Interventions
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01412944
- Locations
- 🇸🇰
Novartis Investigative Site, Kosice, Slovak Republic, Slovakia
Everolimus in de Novo Kidney Transplant Recipients
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 383
- Registration Number
- NCT01410448
- Locations
- 🇮🇹
Novartis Investigative Site, Novara, Italy
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 138
- Registration Number
- NCT01407003
- Locations
- 🇺🇸
Novartis Investigative Site, Miami, Florida, United States
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- Drug: AIN457 300mgDrug: AIN457 150mg
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 967
- Registration Number
- NCT01406938
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT01404325
- Locations
- 🇩🇪
Novartis Investigative Site, Muenchen, Germany
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01402440
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇬🇧Novartis Investigative Site, Manchester, United Kingdom
🇺🇸Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State, Columbus, Ohio, United States
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT01402401
- Locations
- 🇺🇸
University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, United States
🇺🇸University of Texas/MD Anderson Cancer Center UT SC, Houston, Texas, United States
🇪🇸Novartis Investigative Site, Barcelona, Cataluña, Spain